Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NEURAMATE vs KEPPRA XR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NEURAMATE is a brand name for pentobarbital, a barbiturate that enhances GABA-A receptor activity by binding to the barbiturate binding site, increasing the duration of chloride ion channel opening, thereby producing CNS depression.
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.
Short-term treatment of insomnia,Preoperative sedation,Emergency management of acute seizure episodes,Induction of coma for intracranial pressure reduction
Adjunctive therapy for partial-onset seizures in adults and children aged ≥4 years,Adjunctive therapy for myoclonic seizures in adults and adolescents aged ≥12 years with juvenile myoclonic epilepsy,Adjunctive therapy for primary generalized tonic-clonic seizures in adults and children aged ≥6 years with idiopathic generalized epilepsy
250 mg orally three times daily; maximum 1000 mg/day.
1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.
6-8 hours (normal renal function); prolonged to 12-20 hours in moderate renal impairment.
7.1 ± 1.1 hours in adults; 10–11 hours in elderly; prolonged in renal impairment (up to 25 hours in severe renal failure).
Primarily hepatic via hydroxylation and conjugation; involves CYP450 enzymes (CYP2C9, CYP2C19); active metabolites; excreted renally.
Metabolized primarily by hydrolysis of the acetamide group via enzymatic hydrolysis (not CYP450 dependent); forms inactive metabolite (UCB L057); ~24% of dose undergoes oxidative metabolism.
Primarily renal (90% unchanged) with 10% biliary/fecal.
Renal: 66% as unchanged drug; 27% as inactive metabolite (uch L057); biliary/fecal: negligible (<1%).
<10% (albumin).
<10%; binding to albumin (not extensive).
0.8 L/kg (suggests distribution into total body water).
0.5–0.7 L/kg; suggests distribution into total body water.
Oral: 98%; IM: 90%.
100% for oral tablet (immediate-release); 100% for extended-release (relative to immediate-release).
GFR 30-59 m L/min: 250 mg twice daily; GFR 15-29 m L/min: 250 mg once daily; GFR <15 m L/min: 250 mg every other day.
For Cr Cl > 80 m L/min: 1500 mg once daily; Cr Cl 50-80 m L/min: 1000 mg once daily; Cr Cl 30-49 m L/min: 500 mg once daily; Cr Cl < 30 m L/min: 250 mg once daily. ESRD on dialysis: 500 mg once daily with 250 mg supplemental dose post-dialysis.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75%.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), reduce dose by 50%.
For children 2-12 years: 10 mg/kg/day in 3 divided doses, increasing over 2 weeks to 30 mg/kg/day; maximum 60 mg/kg/day.
For children ≥12 years (≥40 kg): 1500 mg orally once daily. Not FDA-approved for <12 years; use immediate-release formulation for pediatric patients <12 years: starting dose 10 mg/kg twice daily, titrated to 30 mg/kg twice daily.
Initiate at 125 mg twice daily; titrate slowly; monitor renal function and adjust based on creatinine clearance.
Elderly patients often have reduced creatinine clearance; dose should be adjusted based on renal function. Monitor for drowsiness, dizziness, and ataxia. Start at lower end of dosing range and titrate cautiously.
Risk of respiratory depression, especially when administered intravenously; risk of dependence and withdrawal; not for use in patients with porphyria.
No FDA black box warning.
Respiratory depression; hypotension; paradoxical excitation; risk of abuse and dependence; withdrawal seizures upon abrupt discontinuation; use with caution in hepatic/renal impairment; elderly patients; pregnancy category D.
Behavioral abnormalities including psychosis, aggression, hostility, irritability, and suicidal ideation/behavior,Somnolence and fatigue,Serious dermatologic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic abnormalities (decreased red blood cell, white blood cell, and platelet counts),Increased blood pressure in pediatric patients,Withdrawal seizures upon abrupt discontinuation
History of porphyria; severe respiratory insufficiency; hypersensitivity to barbiturates; pregnancy (especially third trimester); breastfeeding; myasthenia gravis; acute or chronic pain.
Hypersensitivity to levetiracetam or any component of the formulation
Food does not significantly alter absorption. Avoid grapefruit juice as it may inhibit metabolism and increase toxicity. Maintain adequate hydration to reduce risk of nephrolithiasis.
No significant food interactions. Grapefruit juice does not affect levetiracetam. Avoid alcohol as it may exacerbate CNS depression.
NEURAMATE is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 4-fold increased risk of major congenital malformations, particularly neural tube defects (spina bifida, anencephaly), orofacial clefts, and cardiovascular anomalies. Second and third trimester exposure is linked to decreased IQ scores, autism spectrum disorders, and neurodevelopmental delays in offspring. Neonatal withdrawal syndrome (hyperirritability, feeding difficulties, respiratory distress) may occur with third trimester exposure.
Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy association unclear but may be dose-dependent. Second/third trimester: Risk of fetal growth restriction, hemorrhagic disease of newborn (vitamin K deficiency due to enzyme induction). Perinatal: Neonatal withdrawal syndrome, sedation, and coagulopathy.
NEURAMATE is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.8–1.0. Infant serum levels can reach 10–20% of maternal therapeutic concentrations. Breastfeeding is not recommended due to risk of infant sedation, poor suckling, and potential long-term neurodevelopmental effects. If breastfeeding is essential, monitor infant for excessive drowsiness, feeding problems, and weight gain.
Levetiracetam is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Relative infant dose is low (2–7% of weight-adjusted maternal dose). Limited data suggest no adverse effects in breastfed infants, but monitor for drowsiness, poor feeding. Benefit likely outweighs risk in most cases.
Pregnancy reduces NEURAMATE serum concentrations by 50–70% due to increased volume of distribution, enhanced hepatic clearance (CYP2C9 induction by estrogens), and decreased albumin binding. Total daily dose may need to be increased by 30–50% above prepregnancy baseline to maintain therapeutic trough levels (50–100 mcg/m L). Administer in 3–4 divided doses to minimize peak-to-trough fluctuations. Monitor serum levels every 2–4 weeks and adjust dose accordingly. Postpartum, reduce dose to prepregnancy level within 1–2 weeks to avoid toxicity.
Increased clearance of levetiracetam during pregnancy, particularly in the second and third trimesters (up to 50–60% higher). Dose adjustments may be required to maintain therapeutic trough levels (target 12–46 µg/m L). Consider therapeutic drug monitoring every 1–3 months and after delivery, with gradual dose reduction to pre-pregnancy levels within 1–2 weeks postpartum.
NEURAMATE (felbamate) is a second-line antiepileptic due to risk of aplastic anemia and hepatotoxicity. Obtain informed consent, baseline CBC and LFTs, and monitor closely. Titrate slowly to minimize sedation. Not first-line for any indication.
Keppra XR (levetiracetam extended-release) is dosed once daily due to its prolonged absorption profile. Therapeutic drug monitoring is not routinely required because of its predictable pharmacokinetics and wide therapeutic index. Adjust dose in renal impairment (Cr Cl < 80 m L/min) using ideal body weight; supplement dose after hemodialysis. May cause somnolence, dizziness, and behavioral changes (e.g., aggression, psychosis) especially in pediatric and elderly patients. Stevens-Johnson syndrome and angioedema are rare but serious adverse effects. Sudden discontinuation may precipitate withdrawal seizures; taper over at least 2 weeks.
Report any signs of infection, bruising, or bleeding immediately.,Report jaundice, abdominal pain, or dark urine promptly.,Do not stop abruptly; taper under medical supervision to avoid withdrawal seizures.,May cause dizziness, ataxia, or sedation; avoid driving until effects known.,Use effective contraception; felbamate reduces oral contraceptive efficacy.
Take exactly as prescribed once daily with or without food, at the same time each day.,Swallow tablet whole; do not crush, chew, or break.,Do not drive or operate heavy machinery until you know how this medicine affects you.,Contact your doctor immediately if you experience skin rash, blistering, swelling of face/lips, or difficulty breathing.,Inform your doctor of any history of depression, mood swings, aggressive behavior, or suicidal thoughts.,Report any worsening of seizures or new types of seizures.,If you are on dialysis, take the recommended supplement dose after each session.,Do not stop taking this medicine suddenly as it may cause withdrawal seizures.,Avoid alcohol while taking Keppra XR; it may increase drowsiness and dizziness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NEURAMATE vs KEPPRA XR, answered by our medical review team.
NEURAMATE is a Antiepileptic that works by NEURAMATE is a brand name for pentobarbital, a barbiturate that enhances GABA-A receptor activity by binding to the barbiturate binding site, increasing the duration of chloride ion channel opening, thereby producing CNS depression.. KEPPRA XR is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NEURAMATE and KEPPRA XR depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NEURAMATE is: 250 mg orally three times daily; maximum 1000 mg/day.. The standard adult dose of KEPPRA XR is: 1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NEURAMATE and KEPPRA XR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NEURAMATE is classified as Category C. NEURAMATE is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 4-fold increased risk of major congenital malformations, particularly neural tube. KEPPRA XR is classified as Category C. Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.